The drugmaker posted April–June operating profit of EUR 176.6 million and cited higher Nubeqa royalty income, while highlighting ODM-212 milestones and FDA approval for Tessie.
Orion lifted the lower end of its 2026 guidance after a strong second quarter, with April–June net sales rising 25.2% to EUR 521.6 million and operating profit climbing 68.8% to EUR 176.6 million. For January–June, net sales totalled EUR 939.3 million and operating profit reached EUR 291.3 million. The company now expects 2026 net sales of EUR 2,000 million to EUR 2,100 million and operating profit of EUR 650 million to EUR 750 million, compared with earlier ranges of EUR 1,950 million to EUR 2,100 million and EUR 600 million to EUR 750 million. President and CEO Liisa Hurme said Innovative Medicines remained the main growth driver, Branded Products also grew strongly, and profitability improved largely because of higher Nubeqa royalty income. Orion also pointed to progress for clinical-stage asset ODM-212, including a Phase 1b/2 study initiation, ASCO Phase 1 data and orphan designations for mesothelioma, while the FDA (U.S. Food and Drug Administration) approved Animal Health product Tessie for dogs.